OncoAlert: Recent Episodes
OncoAlert
🚨 Oncología Ahora y en Directo | Avances en Cáncer de Vejiga Avanzado
En este episodio, las Dras. @nataliagandur 🇦🇷 y @ReginaBarCar 🇲🇽 analizan los avances más recientes en el tratamiento del carcinoma urotelial localmente avanzado y metastásico, destacando el impacto transformador de la inmunoterapia perioperatoria y las combinaciones con anticuerpos conjugados (ADCs).
👉 Basado en estudios clave como NIAGARA, EV-301, EV-302 y CheckMate 901, el episodio explora cómo estas estrategias están redefiniendo los estándares internacionales en #BladderCancer.
💡 Las expertas también discuten los desafíos de acceso y equidad en América Latina, donde las barreras estructurales y regulatorias dificultan la implementación de terapias innovadoras.
🌎 Con una mirada crítica y comprometida, las Dras. Gandur y BarCar resaltan la importancia de adaptar las guías globales a entornos con recursos limitados, impulsar la participación en ensayos clínicos regionales, y promover consensos locales que reflejen la realidad de nuestros pacientes.
🎯 Conclusión: La oncología debe ser un derecho universal, no un privilegio.
📲 Suscríbete a OncoAlert360 para no perderte los próximos episodios de Oncología Ahora y en Directo con líderes en investigación y práctica clínica.
🎙️ Oncology Here & Now Podcast | Season 2, Episode 3
In this episode, we explore HER2-positive advanced breast cancer with a leading experts in the field Dr. Elisa Agostinetto and Dr. Erika Hamilton. We discuss the evolving treatment landscape, including first-line standards like the CLEOPATRA regimen and the latest DestinyBreast09 results from ASCO, and practical strategies for patient selection and toxicity management in daily clinical practice.
Key topics covered in this episode:
– Current standard of care for HER2+ ABC
– Impact of DestinyBreast09 results: Should T-DXd + pertuzumab be used for all patients or select patients?
– Optimal treatment duration: induction vs maintenance strategies
– Monitoring ILD: CT scan frequency and best practices
– T-DXd rechallenge after grade 1 ILD: real-world insights
This episode is a must-listen for oncologists, hematologists, and healthcare professionals seeking practical guidance to improve patient care in HER2+ advanced breast cancer.
🔔 Subscribe for weekly episodes and stay updated on the latest in oncology
Join Dr. Gil Morgan in conversation with Mr. Tyler Kratzer of the American Cancer Society, lead author of Prostate Cancer Statistics 2025 (published in CA: A Cancer Journal for Clinicians).
📖 Read the paper here: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.70028
Key Insights:
⚠️ Racial disparities persist:
Black men: 2× higher mortality & 67% higher incidence
American Indian/Alaska Native men: 12% higher mortality despite lower incidence
Asian American/Pacific Islander & Hispanic men: less often diagnosed with localized disease
👉 Take-home message: Rising rates of advanced prostate cancer and persistent disparities underscore the urgent need to improve early detection strategies, avoid overdiagnosis, and address inequities in outcomes.
The OncoAlert Weekly Roundup is your go-to podcast for the latest, most impactful updates in oncology from across the globe 🌍. Each week, we break down the key studies shaping cancer care—so you stay ahead, in just minutes.
This week’s highlights include:
🔹 PRIME Diagnostic Trial: Bi-MRI vs. mp-MRI in #ProstateCancer
🔹 NECTIN4-CAR T cells show promise in #BladderCancer
🔹 Global consensus on bladder-sparing MIBC trial endpoints
🔹 PREOPANC-2 in resectable #PancreaticCancer
🔹 WU-KONG1B: Sunvozertinib in EGFR exon20 #NSCLC
🔹 Updated ASTRO–ASCO–SSO guideline on PMRT in #BreastCancer
🔹 Impact of sequential ADCs in HER2- MBC
🔹 Sacituzumab govitecan in low-grade serous #OvarianCancer
🔹 OlAnCa Trial: Olanzapine in cancer cachexia
🔹 Nurse-delivered Meaning-Centered Psychotherapy for advanced cancer
👉 Don’t miss an episode—subscribe now for concise, evidence-based insights that matter to your practice.
✨ Stay tuned. Stay informed. Stay #OncoAlert.
El nuevo podcast de OncoAlert 🚨 en nuestro idioma! Con nuestras colegas Dra. Natalia Gandur (Argentina) y Dra. Reginia Barragán (México).
En este primer episodio, las doctoras Barragán-Carrillo y Gandur nos cuentan qué esperar de este webcast enfocado en el tratamiento del cáncer en LATAM y mucho más!
🎧 Disponible aquí y como podcast. ¡Cordialmente invitados!
Temporada 1 Episodio 1
This week on The OncoAlert Weekly Round Up, we spotlight precision oncology in action with top-tier studies making headlines:
🧬 Biomarkers in Breast Cancer Immunotherapy
We break down a critical review by Li et al. and Sherene Loi in The Breast on the evolving biomarker landscape for immune checkpoint inhibitors (ICIs) in breast cancer. PD-L1 isn’t enough—so what’s next? TILs, HRD, TMB, and even signals in luminal tumors might hold the key.
🧪 ER+/HER2+ Subtype Shifts with Preop Endocrine Therapy
A translational analysis from the POETIC trial shows how 2 weeks of aromatase inhibitors can flip high-risk luminal B tumors into luminal A—and change everything about treatment decisions.
🧠 Metabolic Warfare in Brain Metastases
From Nature Reviews Cancer, we explore how cancer cells rewire their metabolism to colonize the brain—and why targeting those pathways could change the game.
🚭 Platinum-Ineligible NSCLC: Real-World Wins for Atezolizumab
Post hoc analysis from IPSOS reinforces immunotherapy’s role for frail lung cancer patients previously excluded from platinum therapy.
🔬 Targeting BRAF in NSCLC: Real-World Outcomes from Turkey
Data from the Turkish Oncology Group reveal the strengths—and survival gaps—of D+T versus chemo, especially in the presence of co-mutations.
💥 Pancreatic Cancer Regimens Face Off in GENERATE Trial
A surprise outcome from JCOG1611 as nab-paclitaxel + gemcitabine outpaces mFOLFIRINOX and S-IROX—raising new questions for front-line care.
🧻 Total Neoadjuvant Therapy in Rectal Cancer: Global Perspective
An international analysis confirms that multiple TNT regimens are working in practice—offering real hope in high-risk stage II/III disease.
⚡ Sequencing Matters in mCRPC
New data suggest enzalutamide before 177Lu-PSMA-617 yields better outcomes than abiraterone—highlighting the power of strategic sequencing.
💸 The Hidden Economic Toll on Cancer Caregivers
A sobering study from Australia puts numbers behind the emotional and financial costs borne by informal cancer caregivers—and calls for policy reform.
🚨 Don’t miss this high-impact episode packed with clinical insights, translational breakthroughs, and real-world data that matter for your daily practice.
📲 Stream now on your favorite podcast app
Welcome to another impactful episode of The OncoAlert Weekly Roundup — your go-to source for the latest breakthroughs in oncology, hosted by Gil Morgan.
🚨 This week, we’re diving deep into where precision meets practicality — from genomic tools redefining risk in breast and lung cancer, to combination therapies setting new standards, and even exercise as a tool in metastatic prostate cancer.
🧬 Highlights include:
- Groundbreaking data on HER2DX and ctDNA in early-stage cancer
- Long-term FLAURA2 results showing improved survival in EGFR-mutant NSCLC
- A compelling review on the anti-cancer potential of exercise in advanced prostate cancer
- The science behind epithelial–mesenchymal transition (EMT) and why it matters now more than ever
💡 Whether you're a clinician, researcher, or cancer care advocate, this week’s roundup gives you the insights you need to stay ahead in the rapidly evolving world of oncology.
👇 Don’t forget:
✅ Subscribe for weekly updates
📬 Sign up for our newsletter: www.oncoalert360.com
📢 Share with colleagues & join the conversation in the comments
🔔 Hit the bell so you never miss an update
From game-changing trial results to the evolving science behind personalized cancer care, this week’s OncoAlert Round Up dives into the most impactful studies shaking up the oncology landscape. We explore the TALAPRO-2 trial’s final analysis showing that talazoparib plus enzalutamide significantly improves survival in men with HRR-deficient mCRPC—especially those with BRCA1/2 alterations—positioning it as a potential new standard of care. Plus, we unpack new insights into geriatric assessment in oncology, breastfeeding post–HR+ breast cancer (POSITIVE trial), non-clear cell RCC, brain metastases at single-cell resolution, MMR-deficient cancer treatment, microbiome modulation, and more. Whether you're a clinician, researcher, or just passionate about cancer science, this episode delivers everything you need to stay ahead.
Listen now and subscribe for your weekly dose of cutting-edge cancer care.
The @OncoAlert Round Up Covering July 26-Aug 1, 2024
REGISTER at http://Oncoalert360.com or https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration
Discussing
Shield Blood test FDAApproved for #ColorectalCancer Screening
https://ascopost.com/news/july-2024/guardant-health-s-shield-blood-test-approved-by-the-fda-as-a-primary-screening-option-for-colorectal-cancer/
INSIGHT Trial in #NSCLC
https://thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00270-5/abstract
Combining PSMA-PETand PROMISE in #ProstateCancer
https://sciencedirect.com/science/article/pii/S1470204524003267
Review in RCC #KidneyCancer
@b_szabados
@drfrankiejs
@tompowles1
https://thelancet.com/journals/lancet/article/PIIS0140-6736(24)00917-6/abstract
Immune & Gene Expressionin ER Low & Neg #BreastCancer by
@vitti10
https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djae178/7724836?searchresult=1&login=false
Top Advances of the year: #Immunotherapy & #EndometrialCancer
@BanerjeeSusana
@PelegHasson
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35417
ASCOGuidelines on cannabis in Adults Cancer
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35461?af=R
Welcome to this Hematology Round Up from #EHA24
WE have focused on on Hematologic malignancies with abstracts presented on June 15nd, 2024
The first presentation was abstract s100
This Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) .
Presented by Dr. Facon
This trial presentation had a concomitant publication on the @NEJM
at #ASCO24 last week
https://lnkd.in/d2dRh6Hp
The Second presentation was abstract S101
THE LANDSCAPE OF TP53 MUTATIONS AND THEIR PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKEMIA
https://lnkd.in/dYg6DqPT
The Next presentation was abstract S102
FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA
https://lnkd.in/d2ZM6Z4Q
The Next presentation is abstract S103
ASCIMINIB (ASC) PROVIDES SUPERIOR EFFICACY AND EXCELLENT SAFETY AND TOLERABILITY VS TYROSINE KINASE INHIBITORS (TKI) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN THE PIVOTAL ASC4FIRST STUDY
https://lnkd.in/dxiets8m
Our final Presentation is Late breaking abstract 3438
GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)
https://lnkd.in/dMWxnyF4
Thank you for your attention and enjoy #EHA24
Disclosure: This Hematology Round Up was supported by Sanofi
Dear Colleagues,
Welcome to this Hematology Round Up from
hashtag
ASCO24 . WE have focused on Hematologic malignancies with 3 presentations which were presented on June 2nd, 2024
The first presentation was the Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) . Presented by Dr. Facon
This trial presentation came with a concomitant publication on the New England Journal of Medicine (NEJM).
https://lnkd.in/d2dRh6Hp
The Second Presentation was the Phase 3 randomized BENEFIT study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). Presented by Dr. Leleu
This trial presentation came with a concomitant publication on Nature Medicine
https://lnkd.in/dSjVvk7X
The final presentation was Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Presented by Dr Rodriguez-Otero
Dr. Landgren discussed how quadruple therapies showed higher rates of minimal residual disease (MRD) and longer progression-free survival compared to triplets, regardless of age and transplant eligibility, potentially making them a new standard of care for newly diagnosed Multiple Myeloma.
He emphasized the importance of minimal residual disease as an endpoint in newly diagnosed multiple myeloma, suggesting that having it as an early endpoint for accelerated approval could give patients faster access to new therapies. However, he also highlighted that bortezomib increases the rate of peripheral neuropathy.
Dr. Landgren pointed out that CD38 monoclonal antibodies narrow the gap between transplant-eligible, younger, and fit patients, and transplant-ineligible, older, and less fit patients with multiple myeloma.
Thank you for your attention and enjoy ASCO
Disclosure: This Hematology Round Up was supported by Sanofi
✅ TheLancet Commission on #ProstateCancer
✅DESTINY-PanTumor01
✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁
✅ASCENT in Triple Negative #BreastCancer 🧪
✅Bilateral Oophorectomy in BRCA1&2🧬
✅Racialized inequities in live birth after cancer🤰🏾
✅MITO END in Endometrial Cancer
✅Tx Patterns Advanced Urothelial Carcinoma🇺🇸
and more‼️
The OncoAlert Weekly Round Up 🚨Covering April 26- May 1st, 2024
REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration
COVERING
DESTINY-Breast06
Monarch E
US Preventive S Task force #BreastCancer Screen
@US_FDA approval of Tisotumab vedotin
NEO predict-Lung
Pushing Boundaries in ctDNA
StereotactiveRT in oligomet #KidneyCancer
Thromboembolic Risk in #ProstateCancer Patients Treated with PARP Inhibitors
@CancerCareMASCC - @ASCO Standards and practices in metastatic #Cancer
Special Podcast:
@gu_onc & @Uromigos at #APCCC24
What happens when Five Friends initially brought together by oncology meet up in Lugano for #APCCC24..........Magic...thats what!
Join Renu, Declan, Brian, Tom and Gil on this insanely casual and fun conversation on the side
The OncoAlert Weekly Round Up
Covering April 19-25, 2024
REGISTER AT http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration
Discussing
ADCs in #LungCancer & #BreastCancer
Out on
@Annals_Oncology
https://annalsofoncology.org/article/S0923-7534(24)00108-X/abstract
TILS in #TNBC
https://jamanetwork.com/journals/jama/article-abstract/2816923
TROPION in #BreastCancer
https://ascopubs.org/doi/full/10.1200/JCO.23.01909
DE-REAL in #BreastCancer
https://academic.oup.com/oncolo/article/29/4/303/7444338?login=false
CheckMate9ER in #kidneycancer
https://esmoopen.com/article/S2059-7029(24)00762-2/fulltext#%20
INNOVATED out on
@ESMO_Open
POP RT in #ProstateCancer
https://redjournal.org/article/S0360-3016(24)00439-5/abstract#%20
Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35333
✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on @NEJM
https://www.nejm.org/doi/full/10.1056/NEJMoa2312695#ap0
✅Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial
https://www.annalsofoncology.org/article/S0923-7534(24)00105-4/fulltext
✅Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00185-X
✅Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab
https://www.jtocrr.org/article/S2666-3643(24)00045-6/fulltext
✅The Lancet Breast Cancer Commission
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00747-5/fulltext
✅Top advances of the year: Uterine cancer
https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35321
The @OncoAlert RoundUp is Out
Covering April 5th-12th, 2024
REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration
Discussing:
@US_FDA
approval trastuzumab dx
Durvalumab in Small Cell #LungCancer
ALINA #NSCLC out on
@NEJM
CD70 CART in #KidneyCancer
Adagrasib Cetux in #colorectalcancer
and more
The Top News, publications and trials in Oncology for the week of March 28- April 4, 2024
SENOMAC out in NEJM on Breast Cancer
ACS & IARC 2022 Cancer Statistics
and more
JAVELIN Renal 101 Out on Cancer Discovery
FASTRACK II Out on Lancet Oncology
ONE SHOT (in Prostate cancer) Out on the Green Journal
SPECIAL LUNG CANCER PODCAST
WCLC23 World Conference #LungCancer
TO GET IT REGISTER AT: http://OncoAlert360.com
FLAURA
MARS
TMN Staging
DESTINY LUNG
Herthena
TRIDENT
EVOKE
ISABR
RIOT
and more
A great way to catch up on all the great Science presented in Singapore
The @oncoAlert Round Up
September 1- 7, 2023
REGISTER TO GET IT at http://OncoAlert360.com
Discussing:
@fda Breakthrough therapy designations for Trastuzumab deruxtecan
Sequencing Endocrine & Targeted Txin Hormone sensitive HER2- #breastcancer
Neoadj palbociclib+giredestrant or anastrozole in ER+, HER2- early breast #cancer
Exercise& Nutritionon Chemo Completion & pCR in Breast #Cancer
Bladder-Sparing Treatment w/ Radical Dose RT Is Effective Alternative to Radical Cystectomy in Node+ Nonmets and more...
Discussing:
EMAapproval of Pembro+Trastuzumab+Chemo in Gastric Cancer based on KeyNote 811
LUNARin metastatic #NSCLC
ASTRRAin #BreastCancer
Cannabinioidsin children with #Cancer
IO in treatment of Localised GU Cancers
LMWH synergistically enhances efficacy of adoptive and anti-PD-1-based #Immunotherapy
.....and more
Register at www.oncoalert360.com
Discussing:
EMAapproval of Pembro+Trastuzumab+Chemo in Gastric Cancer based on KeyNote 811
LUNARin metastatic #NSCLC
ASTRRAin #BreastCancer
Cannabinioidsin children with #Cancer
IO in treatment of Localised GU Cancers
LMWH synergistically enhances efficacy of adoptive and anti-PD-1-based #Immunotherapy
.....and more
Register at www.oncoalert360.com
LITESPARK005 in #KidneyCancer
TBCRC 030 in TN #BreastCancer
CONTACT02in #prostatecancer
MRIto help diagnose #ProstateCancer
LIBRETTO 531in #ThyroidCancer
SBRT in HCC #LiverCancer
REGISTERto get it www.OncoAlert360.com
Discussing:
@US_FDA approval of LONSURF+Bev in CRC
selpercatinib in RET+ #NSCLC
erdafitinib in Tumor Agnostic setting: RAGNAR
Cause Specific Mortalityof Race & Ethnicity
Stereotactic Body Reirradiationin Gyn Cancer
Depression, anxiety & #Cancer Risk
and more
Case Discussion
Localised High Risk #ProstateCancer
58yr old male
DRE: Hard mass c3
PSA 12.4
Gleasons 4+5=9
Imaging M0
later PSMA M1 in bone
Faculty
Dr. Neeraj Agarwal
Dr. Eleni Efstathiou
Dr. Axel Merseburger
Dr. Sean McBride
Dear Colleagues,
Welcome to the ASCO22 RoundUp for Day one of the congress
Starting with with KRYstal1 with a concomitant publication in the New England
Phase One report of Adagrasib in Non Small Cell Lung Cancer, targeting KRAS G12C shows promise in clinical efficacy without new safety signals
Large number of response
median follow-up of 12.5 months
the median PFS 6.5 months
median OS 12.6 months
The EVEREST Trial
Adjuvant everolimus improves RFS in resected renal cell carcinoma in over 1,500 patients
6-year estimated RFS was 64% for everolimus Vs 61% placebo.
Just missing respecified 0.0222 significance.
That is a minimal improved RFS with significantly higher AEs.
There was a 21% improvement in RFS in everolimus in those with high risk for recurrence with no benefit seen in those in an intermediate high-risk group.
Update of COSMIC-021 Trial
This was first-line treatment in urothelial carcinoma
Combining Cabo/Atezo shows encouraging results with manageable tox
in patients who were
ineligible for cisplatin
cisplatin eligible
or with 1 prior immune checkpoint inhibitor and no prior VEGF TKIs
OR 20% in cisplatin-ineligible patients,
30% in cisplatin-eligible patients,
10%for those w prior ICI.
Lung-MAP S1800A
in Second-line pembrolizumab plus ramucirumab in Non Small Cell Lung Cancer
Here there was a possible survival benefit with immune checkpoint inhibitor resistance VS Standard of care
This is the first successful trial in the second-line setting for advanced NSCLC in those withAcquired resistance to immune checkpoint inhibitor therapy with out a Chemo backbone
Great to see lung cancer patients who progressed on prior immunotherapy, living significantly longer when treated with the combo of Pembrolizumab plus ramucirumab
OS 14.5 months vs 11.6 months
Very encouraging
Checkmate 9ER
Depth of response to nivolumab plus cabozantinib is associated with durable efficacy and improved prognosis in previously untreated advanced renal cell carcinoma
The 12-month PFS rate for patients with the deepest responses in nivo cabo was 46.2% Vs 27.4% in sunitinib.
The 18-month OS rate was twice as high in nivolumab plus cabozantinib 37.9% vs 17.4%)
An improvement in Prognosis!
And those are just SOME of the top trials presented at DAY1 of ASCO22
Looking forward to an Amazing Day 2
Reminding everyone to mask up and enjoy ASCO
41 year female, no past medical history
Comes to MedOnc after left breast lumpectomy & SN evaluation
Path: 2.1 cm grade 2 tumor
ER 100%
PR 90%
Her2 1+ FISH-
1/2 Sentinel Node positive (4mm tumor deposit w/extranodal extension)
Systemic staging-
OncotypeDX 20
BreastCancer #OncoAlertTB
Dr. Hamilton
Dr. Lustberg
Ms. Mapes
Dr. Lambertini
Dr. Meattini
Moderators
Dr. Grainne O'kane
Dr. Ben Westphalen
Host
Dr. Gil Morgan
The case
42 year old female never smoker
Comes to the ER with sudden onset chest pain
Radiology finds 4.2cm left-sided lung mass & enlarged mediastinal LN on staging PET/CT and Brain MRI.
Staged as cT2bN2 (Stage IIIA) #NSCLC
Surgically resectable
lungcancer #LCSM #OncoAlertTB
Experts
Dr. Narushka Naidoo
Dr. Jack West
Dr. Brendon Stiles
Dr. Henning Willers
Dr. Christian Rolfo
Moderators
Dr. Grainne O'kane
Dr. Ben Westphalen
Host
Dr. Gil Morgan
First data from CODEBREAK
Sotorasib in G12C mutant Pancreatic Cancer
Presented Feb 15, 2022 by Dr. John Strickler of Duke Medical Center